



Title	Induction chemotherapy for squamous cell carcinomas of the oral cavity: A cumulative meta-analysis
Author(s)	Lau, A; Li, KY; Yang, WF; Su, Y
Citation	Oral Oncology, 2016, v. 61, p. 104-114
Issued Date	2016
URL	http://hdl.handle.net/10722/238629
Rights	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Manuscript Number: OO-D-16-344

Title: Induction Chemotherapy for Squamous Cell Carcinomas of the Oral Cavity: A Cumulative Meta-analysis

Article Type: Review Article

Section/Category: Basic

Keywords: oral cancers, mouth neoplasm, induction chemotherapy, adjuvant chemotherapy, meta-analysis, systematic review

Corresponding Author: Dr. Yu-xiong Su, MD, DDS, PhD

Corresponding Author's Institution: the University of Hong Kong

First Author: Ashley Lau , MBBS, BSc

Order of Authors: Ashley Lau , MBBS, BSc ; Kar Yan Li , MPhil, BSc ; Wei Fa Yang , DDS ; Yu-xiong Su, MD, DDS, PhD

Abstract: Induction chemotherapy (ICT) is a controversial treatment for head and neck squamous cell carcinomas (HNSCC). Despite numerous randomized controlled trials (RCTs), a majority do not have enough statistical power alone to conclude ICT's treatment value among oral squamous carcinoma patients (OSCC) since many addressed HNSCC as one entity instead of by specific subtypes. By performing a systematic review and cumulative meta-analysis, we aim to determine the benefits of ICT in OSCC therapy. A literature search identified for RCTs comparing OSCC patients who received ICT against those without. Log-hazard ratio, and relative risk were used for comparison. Heterogeneity was determined using the I2 statistic package. The primary endpoint was overall survival (OS), followed by disease-free survival (DFS), locoregional recurrence (LRR) and distant metastasis (DM) as secondary endpoints. RESULTS: 27 randomized trials were included for analysis (n= 2872 patients). The shortest median follow-up was 15 months whereas the longest was 11.5 years. ICT does not improve OS (HR = 0.947, 95% CI 0.85-1.05, p= 0.318), DFS (RR= 1.05, 95% CI 0.92-1.21, p= 0.462) and DM (RR= 0.626, CI 95% 0.361-1.086, p= 0.096) compared to locoregional treatment alone. However, there was a significant improvement to LRR (RR= 0.778, 95% CI 0.622-0.972, p= 0.027). There is no evidence ICT improves survival outcomes for OSCC patients. However, ICT reduces locoregional recurrence of OSCC, which may need further verification.

Highlights:

- ICT provides no additional benefit to OS, DFS, and DM endpoints for OSCC survival
- LRR may be improved with the addition of ICT in OSCC treatment
- A cumulative meta-analysis is an effective tool to visualize and identify survival trends over time and should be considered for use in conjunction with the traditional meta-analysis format

Manuscript Type: Review article

Manuscript title: Induction Chemotherapy for Squamous Cell Carcinomas of the Oral Cavity: A Cumulative Meta-analysis

Authors: Ashley Lau, MBBS, BSc¹; Kar-Yan Li¹, MPhil, BSc; Wei-fa Yang, DDS^{1,2}; Yu-Xiong Su, MD, DDS¹

Corresponding author: Yu-Xiong Su, Associate Professor, Oral and Maxillofacial Surgery, Faculty of Dentistry, The University of Hong Kong, 34 Hospital Road, Sai Ying Pun, Hong Kong SAR, China; +852-2859-0267; richsu@hku.hk

¹Faculty of Dentistry, The University of Hong Kong, 34 Hospital Road, Sai Ying Pun, Hong Kong, China

²Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, China

Funding source

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Word count: 2955 words

Conflict of interest Disclosures: None declared.

Induction Chemotherapy for Squamous Cell Carcinomas of the Oral Cavity: A Cumulative Meta-analysis

Abstract

Induction chemotherapy (ICT) is a controversial treatment for head and neck squamous cell carcinomas (HNSCC). Despite numerous randomized controlled trials (RCTs), a majority do not have enough statistical power alone to conclude ICT's treatment value among oral squamous carcinoma patients (OSCC) since many addressed HNSCC as one entity instead of by specific subtypes. By performing a systematic review and cumulative meta-analysis, we aim to determine the benefits of ICT in OSCC therapy. A literature search identified for RCTs comparing OSCC patients who received ICT against those without. Log-hazard ratio, and relative risk were used for comparison. Heterogeneity was determined using the I^2 statistic package. The primary endpoint was overall survival (OS), followed by disease-free survival (DFS), locoregional recurrence (LRR) and distant metastasis (DM) as secondary endpoints. RESULTS: 27 randomized trials were included for analysis (n= 2872 patients). The shortest median follow-up was 15 months whereas the longest was 11.5 years. ICT does not improve OS (HR = 0.947, 95% CI 0.85-1.05, p= 0.318), DFS (RR= 1.05, 95% CI 0.92-1.21, p= 0.462) and DM (RR= 0.626, CI 95% 0.361-1.086, p= 0.096) compared to locoregional treatment alone. However, there was a significant improvement to LRR (RR= 0.778, 95% CI 0.622-0.972, p= 0.027). There is no evidence ICT improves survival outcomes for OSCC patients. However, ICT reduces locoregional recurrence of OSCC, which may need further verification.

Key Words: oral cancers, mouth neoplasm, induction chemotherapy, adjuvant chemotherapy, meta-analysis, systematic review

INTRODUCTION

Squamous cell carcinomas of the oral cavity (OSCC) is the 10th most common malignancy worldwide¹. The aggressive nature of advanced OSCC usually indicates a poor prognosis, requiring a multi-nodal treatment strategy of chemotherapy, surgery and radiotherapy. Despite advances in treatment options, locoregional recurrence (LRR) and distant metastasis (DM) rates remain high at around 30% and 25% respectively with minimal improvement to 5-year survival rates as they remain approximately at 50%^{1,2}. While guidelines from the National Comprehensive Cancer Network recommend surgical excision followed by concurrent single-agent cisplatin chemoradiotherapy in T3 or T4 lesions demonstrating adverse features of extrascapular spread and/or positive margins³, the most optimal approach for managing advanced OSCC is still unclear.

The introduction of induction chemotherapy (ICT) showed promise for improving survival in advanced head and neck cancers from the high response rates to ICT demonstrated by trials in the 1990s^{4,5}. It was hypothesized ICT would increase overall survival (OS), disease-free survival (DFS) and progression free survival by improving distant control⁶. Shrinking tumor volume prior to definitive treatment with ICT could enhance radiotherapy feasibility and tolerability whilst reducing the disfiguring effects of surgery and radiation⁶.

Multiple randomized trials (RCT) have evaluated OSCC response to ICT. Integration of data from independent studies is performed through meta-analysis where data from individual trials are pooled simultaneously to provide a summary for evidence-based care. Despite its perceived advantages, multiple meta-analyses did not find significant improvements to OS when ICT was added to treatment⁷⁻¹². However, interest in ICT has been renewed by the improved efficacy to survival using a taxane regimen, and improved loco-regional control by concomitant chemo-radiotherapy (CCRT)¹⁰.

Complementary to the 'traditional' method of meta-analysis, the 'cumulative' meta-analysis approach creates repeated poolings as each new study is added¹³. The overall analysis becomes a continuum of accumulating data, offering a visual depiction of trends and when significance, or if any significance of an endpoint had been achieved over the years for safety and ethical monitoring.

Due to the enduring uncertainty of ICT's role and the continued publications of RCTs investigating ICT in OSCC treatment, this paper aims to summarize the effect of ICT in OSCC treatment by performing an updated systematic review and cumulative meta-analysis from the earliest to most recent published studies.

METHODS AND MATERIALS:

This systematic review followed the Cochrane Collaboration Handbook of Interventions Systematic Reviews and the PRISMA statement checklist and flowchart. Cumulative meta-analysis was performed where studies were added in order of date to summarize the evaluated endpoints.

Search Methods

A sensitive search protocol was developed to retrieve RCTs published in peer-reviewed journals from 1980 to March 2016 using MEDLINE via Pubmed (1970–March 2016), EMBASE via Ovid (1980–March 2016), The Cochrane Central Register of Controlled Trials (CENTRAL) (1970- March 2016), and Web of Science (1956- 2016).

Search queries included MeSH terms for *“Head and Neck Neoplasms”*, *“mouth neoplasms”*, *“gingival neoplasms”*, *“palatal neoplasms”*, *“tongue neoplasms”*, *“lip neoplasms”*, *“mouth squamous cell carcinoma”*, *“induction chemotherapy”*, *“neoadjuvant therapy”*, and *“anti-neoplastic drugs”* in combination with free text phrases such as *“primary chemotherapy”*, *“initial chemotherapy”* and *“oral cavity”*. The syntax input was revised for each database. The Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity maximizing version (revision): PubMed Format was applied for the MEDLINE search whilst the EMBASE search strategy was combined with the Cochrane Oral Health Groups’ RCT filter to maximize retrieving clinical trial articles.

To identify for any current ongoing or missed trials from the search queries, ClinicalTrials.gov and manual searches of reference lists from relevant systematic reviews and meta-analyses, and abstract conferences were screened. No language restrictions were imposed.

Study Selection Criteria

Studies included had the following characteristics:

1. **Participants:** Patients diagnosed only with previously untreated primary OSCC with or without nodal involvement or metastasis.
2. **Types of interventions:** Patients randomized to either receive or not receive ICT with their definitive treatment. All types of chemotherapeutic agents and routes of administration were included. Definitive treatment describes treatment best suited for the patient at the time after all other choices have been considered to eliminate the disease. This could be surgery alone, radiotherapy alone, concurrent chemo-radiotherapy alone, or any of the three in combination.
3. **Outcomes:** Primary outcome is to assess whether ICT improves OS. Secondary outcomes will evaluate DFS, LRR, and DM. If a study only provided figures on secondary outcomes, it was still included only into relevant sections of this analysis.
4. **Studies:** RCTs

Studies were excluded if:

1. Trial was not a RCT
2. Patients had received prior intervention
3. Secondary or recurrent OSCC
4. Other histological types of oral cancer
5. ICT was not compared to locoregional treatment alone
6. Radiotherapy was included in the induction protocol

Study selection and data extraction

Two authors independently reviewed for studies that met the eligibility criteria. An initial screen was performed through reading the title/abstract. If the title/abstract was unclear whether a study fulfilled the inclusion criteria, a full article was obtained. Characteristics of excluded studies were documented and counterchecked by each author. Any disagreements or inconsistencies were resolved amongst group discussion. The corresponding author was contacted for the availability of individual data on OSCC patients in trials which included general head and neck cancer patients, or if clarifications were required. Studies comparing multiple ICT regimens against one control had the interventions combined into a large cohort to avoid inflating sample size data from double-counting the control groups.

Assessment of Bias

Following the Cochrane Collaboration's Tool (Cochrane Handbook version 5.1.0), a risk of bias assessment was conducted from the following domains: sequence generation, allocation concealment, complete outcome data, selective outcome reporting and other potential bias. Outcome data was considered complete if less than 20% of patients randomized were excluded from the trial data with appropriate reasoning described. Blinding of participants, personnel and outcome assessors was not measured due to the difficulty and unethicity of performing a double-blinded trial under such circumstances. The absence of blinding should not affect OS statistics but may influence DFS, LRR and DM reporting. If it was difficult to interpret bias risk from the published article, the study authors were contacted for clarification. An "unclear risk of bias" would be concluded if the author could not be reached and if the available information was insufficient for a proper bias assessment. The Beggs and Egger's

regression test would also be used for OS, and for any endpoints that achieved significance as a supplement to compensate for studies categorized with an “unclear risk” from the Cochrane risk of bias assessment tool.

Data analysis

OS was expressed as log hazard ratios (HR). If HR were not reported yet other statistics were available (observed events, expected events, variance), HR, standard error and 95% confidence intervals were calculated using various formulas provided by Hackshaw 2009¹⁴ and the GraphPad Software Statistics Guide¹⁵.

Other dichotomous outcomes including DRS, LRR and DM were expressed as risk ratios (RR) together with 95% confidence intervals based on the availability of data from these endpoints. A p value of < 0.05 indicated a significant result for all outcomes measured.

Data analysis was performed using STAT/SE ®, version 11 [Stat Crop., College Station, TX, USA]. Heterogeneity was evaluated based on the I^2 statistic percentage or p-value (p< 0.05 indicates significant heterogeneity) to evaluate whether variability in results were attributed to heterogeneity rather than by sampling error.

If heterogeneity was not significant, the Fixed-Effects Model of Mantel and Hanszel with the assumption all trials shared a common effect size would be used.

RESULTS

Selection of trials

From the database query, 2021 reports were organized into a bibliographic database (Figure 1). After removing duplicate articles, 1876 articles were excluded based on assessing the title and abstract. The remaining 145 texts were appraised by full-text. OSCC data published by the MACH-NC Collaborative Group from a meta-analysis performed by Blanchard et al⁷ were also included.

Description of included studies and data analysis

31 RCTs conducted from 1974 to 2015 were initially included. After systematic review, four trials were excluded. One study¹⁶ had high overall bias risk, one did not state whether randomization was performed¹⁷ and two trials from Blanchard's⁷ meta-analysis had no abstract to verify the study data since they were unpublished trials. 22 RCTs included were from the published meta-analysis by the MACH-NC Collaborative Group⁷. Five trials were further identified from the literature search and had data extracted directly from the article. 27 trials were included in the meta-analysis.

Nine studies originated from establishments in France, six from the United States of America, three from Italy, and one each from Australia, Argentina, Brazil, Sweden, Germany Japan, China, India, and Thailand. The earliest trial started recruitment in 1965¹⁸ whilst the most recent completed recruitment in 2008¹⁹. 1484 participants were pooled in the ICT group whereas the control group had 1388 patients for the meta-analysis. 14 RCTs compared the addition of ICT to surgery with/without radiotherapy²⁰⁻³³, 10 against radiotherapy alone^{18,25,26,33-39}, one for CCRT¹⁹, and one study⁴⁰ did not specify the standard therapy given. Regarding ICT regimen, twelve trials evaluated a Cisplatin-5-Fluorouracil containing protocol^{20,21,25,26,32,36-38,40-42}, eight used a Cisplatin-Bleomycin containing protocol^{22,24,28,33,34,36,38,39}, two administered Bleomycin and

Vinorelbine^{23,27}, one included Cisplatin, Bleomycin and 5-Fluorouracil (5-FU)³⁸ and four had other ICT combinations^{18,29-31} where one trial used Cisplatin, 5-FU and Doxorubicin (TPF)³⁰. All trials had OS figures excluding one²³. Five trials reported data for DFS^{19,22,27,30,41}, five for LRR^{19,23,27,30,41}, and four for DM analysis^{19,27,30,41}. OS and DFS were reported from Zhong et al's 2013 paper⁴⁴ instead of the most recent 2015 article³⁰ since the 2015 paper did not provide enough data for OS analysis. The shortest follow-up was at a median of 15 months¹⁹, whereas the longest follow-up period was a median of 11.5 years⁴¹. Further descriptions of the trials included are available in the supplementary data, Table 1.

Risk of Bias assessment

Using the Cochrane risk of bias assessment tool (Figure 2), 7 out of 27 RCTs^{18,22,26,27,29,30,41} were considered low risk of bias. However many studies had insufficient descriptions on how allocations into treatment groups during randomization was performed. 9 Trials^{20,21,23,25,32,37,39,42,43} had large proportions (at least three out of the five domains) of the risk assessment criteria categorized as unclear since insufficient information was provided for an analysis to be made.

One trial¹⁶ had a high risk for bias and subsequently excluded from the analysis. The symmetrical pattern in the funnel plot derived from the Begg's test and calculations from the Egger's test, suggested no evidence of publication bias (see supplementary data figure 1, 2, 3, 4).

Overall Survival

ICT provided no advantage compared to definitive treatment alone for OS (HR= 0.947, 95% CI 0.85-1.05, p= 0.318). Heterogeneity between these groups were not significant (I^2 : 32.3%, p= 0.059). The cumulative meta-analysis plot shows the addition of ICT to locoregional treatment favours neither ICT nor definitive treatment for OS (Figure 3).

Disease Free Survival

There was no significant difference in DFS between patients treated with ICT and patients who only received definitive treatment (RR= 1.05, 95% CI 0.92-1.21, p= 0.462) (Figure 4). Heterogeneity between trials groups were not significant (I^2 =0%, p= 0.556)

Loco-regional recurrence

There was a significant reduction in LRR (RR= 0.778, 95% CI 0.622-0.972, p= 0.027) amongst patients who treated with ICT compared those who only received definitive therapy (Figure 5). Heterogeneity in these trials was not significant (I^2 = 11.3%, p=0.342). When data from Luboinski et al²³ was excluded in a sensitivity analysis, results were not significant (RR= 0.842, 95% CI 0.669-1.060, p= 0.143) and remained non-significant for heterogeneity (I^2 = 0%, p= 0.868) (Figure 6).

Distant metastasis

DM^{19,27,30,41} reduction was not significant between patients in the ICT and control group (RR= 0.626, CI 95% 0.361-1.086, p= 0.096) where heterogeneity between trials was not significant (I^2 = 0%, p= 0.720) (Figure 7).

Discussion

Our paper is the first to include 27 RCTs over a 40-year period, investigating ICT on survival endpoints in a cumulative meta-analysis format. The addition of ICT does not offer an improved OS for OSCC patients. There was also no benefit to DFS, or DM using ICT, with the exception of a significant decrease in LRR for patients receiving ICT.

There continues to be a lack of evidence supporting ICT for routine management in advanced OSCC patients. Previous meta-analyses by Blanchard et al⁷ and Marta et al⁹ found no advantage for OS in patients who had ICT added to their treatment. Although we did not investigate OS based on clinical response to ICT, three studies^{24,30,41} highlighted a correlation between a high clinical response to ICT and improved OS. Whilst it is difficult to ascertain whether the sensitivity was all attributed to chemotherapy, certain HNSCCs such as HPV-positive oropharyngeal cancers are associated with a better therapeutic response to chemo-radiation⁴⁵. This raises the possibility a select group of OSCCs, namely HPV-positive, are more sensitive to ICT. While the role of HPV regarding treatment response and prognosis of OSCC is still controversial and inconclusive, a recent retrospective study demonstrated an improved 2-year OS amongst HPV-positive OSCC patients compared to HPV-negative patients⁴⁶. Therefore, clinical response and HPV status may be important factors contributing towards the success of ICT treatment in OSCC patients. Future studies should investigate these subgroup of patients in correlation with OS to understand whether ICT can truly play a role in OSCC treatment.

The significance observed in LRR reduction for ICT patients may need to be interpreted with caution. When Luboinski et al's²³ trial was excluded in the sensitivity analysis, the effect of ICT on LRR failed to achieve significance ($p= 0.143$). It is important to note

Luboinski et al²³ only reported preliminary results where the trial also had multiple domains categorized as 'unclear' for bias risk. Varying prognostic factors amongst the patient pools could have influenced the sensitivity analysis, and accounted for the unchanged OS despite LRR reduction between the experimental and control cohorts. Luboinski et al²³ had more patients with T2 disease compared to other studies which had a greater number of patients with T3 and T4 disease. Meanwhile, Richard et al²⁷ had more patients with T4 disease assigned to the ICT cohort whilst Bossi et al⁴¹ reported a higher incidence of patient death from unknown causes or treatment toxicity.

Despite an observed reduction in DM for patients who received ICT, our results only approached but never achieved significance (Figure 9). Yet, since Ma et al⁸ demonstrated a significant reduction for DM in HNSCC patients receiving TPF, future studies should further investigate this endpoint for a more conclusive result as our analysis only included 4 trials.

In our meta-analysis, a taxane regimen did not seem to benefit OS considering a shift favoring LRT alone from the forest plot (Figure 3) was observed when a study³⁰ with TPF was included. Meta-analyses by Zhang et al¹² and Kim et al⁴⁷ showed ICT using TPF did not improve OS for HNCC patients, with adverse events cited as a possible risk for increased morbidity and mortality^{12,47}. However, it is too soon to discredit TPF, considering we only included one trial. Kim et al found a significant improvement in OS and PFS for non-oro-pharyngeal head and neck cancer patients who had received TPF treatment⁴⁷. Given oral cancer was the second most prevalent HNSCC subtype included in 3 of the 6 studies within Kim et al's meta-analysis, perhaps ICT using TPF

may provide a breakthrough for OSCC survival. More studies are required to conclude whether TPF has a future role for increasing OSCC survival rates.

A cumulative meta-analysis is frequently criticized for potentially replicating and amplifying biases. Yet, a cumulative and a conventional meta-analysis will present identical results since they are using the same metrics and statistical model. Hence, heterogeneity and the quality of studies will affect both types of analysis equally. A cumulative meta-analysis is reliable for presenting evidence from multiple trials conducted over an extended period of time and should be considered in use with a conventional meta-analyses. As demonstrated in our study, it can aid identifying when and if an intervention ever reaches significance whilst summarizing trends (or the lack of). To tackle concerns about incorporating bias and poor quality studies that would skew the analysis outcomes, systematic reviews should be carried out in conjunction to minimize these risks.

Conclusion

ICT has never provided an improvement to OS for OSCC patients, which can be effectively visualized through a cumulative meta-analysis approach. Although our analysis is the first to demonstrate a statistically significant reduction in LRR amongst patients who received ICT, indicating ICT is possibly effective in managing microscopic disease, these results should also be interpreted with caution.

Figure Legends

Figure 1: A Flow Chart of Literature Search Methods

Figure 2: Risk of Bias Assessment for Trials Identified in the Literature Search

Figure 3: OS between the ICT group and patients who only received definitive therapy

Figure 4: DFS between the ICT group and patients who only received definitive therapy

Figure 5: LRO between the ICT group and patients who only received definitive therapy

Figure 6: A sensitivity analysis of LRO between the ICT group and patients who only received definitive therapy

Figure 7: DM between the ICT group and patients who only received definitive therapy

Acknowledgements: We would like to thank Dr. Paolo Bossi, Dr. Lisa Licitra for their assistance in providing updated results from their trial.

References:

1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. *Oral Oncology*. 2009;45(4):309-316.
2. Gyawali B, Shimokata T, Honda K, Ando Y. Chemotherapy in locally advanced head and neck squamous cell carcinoma. *Cancer Treat Rev*. 2016;44:10-16.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology , Head and Neck Cancers Version 2. <http://oralcancerfoundation.org/treatment/pdf/head-and-neck.pdf>. Published May 29, 2013. Accessed November 12 2015.
4. C. Domenge CH, J.L. Lefebvre, De Raucourt D et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Group d'Etude des Tumeurs de la Tete et du Cou (GETTEC) *Br J Cancer* 2000(83):1594-1598.
5. Paccagnella A, Mastromauro C, D'Amanzo P, Ghi MG. Induction Chemotherapy Before Chemoradiotherapy in Locally Advanced Head and Neck Cancer: The Future? *The Oncologist*. 2010;15(suppl 3):8-12.
6. Busch CJ, Tribius S, Schafhausen P, Knecht R. The current role of systemic chemotherapy in the primary treatment of head and neck cancer. *Cancer Treatment Reviews*. 2015;41(3):217-221.
7. Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. *Radiotherapy and Oncology*. 100(1):33-40.
8. Ma J, Liu Y, Yang X, Zhang C-p, Zhang Z-y, Zhong L-p. Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis. *World Journal of Surgical Oncology*. 2013;11:67-67.
9. Marta GN, Riera R, Bossi P, et al. Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. *European Journal of Cancer*. 2015;51(17):2596-2603.doi:10.1186/1477-7819-11-67.
10. Blanchard P, Bourhis J, Lacas B, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2013;31(23):2854-2860.
11. Qian X, Ma C, Hoffmann TK, Kaufmann AM, Albers AE. Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety. *SpringerPlus*. 2015;4:208.doi: 10.1186/s40064-015-0988-5.
12. Zhang L, Jiang N, Shi Y, Li S, Wang P, Zhao Y. Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis. *Scientific Reports*. 2015;5:10798.doi:10.1038/srep10798.
13. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. *Journal of Clinical Epidemiology*. 1995;48(1):45-57.
14. Hackshaw A. Statistical Formulae for calculating some 95% confidence intervals *A Concise Guide to Clinical Trials*: Wiley-Blackwell; 2009:203-207.
15. GraphPad Software. Survival Analysis- Interpreting results: the hazard ratio. http://www.graphpad.com/guides/prism/6/statistics/index.htm?stat_the_hazard_ratio.htm. Published 1995. Updated 2015. Accessed January 14, 2016.
16. Sadighi S, Keyhani A, Harirchi I, et al. Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study. *Acta medica Iranica*. 2015;53(6):380-386.
17. Umeda M, Komatsubara H, Ojima Y, et al. Lack of survival advantage in patients with advanced, resectable squamous cell carcinoma of the oral cavity receiving induction chemotherapy with cisplatin (CDDP), docetaxel (TXT) and 5-fluorouracil (5FU). *The Kobe journal of medical sciences*. 2004;50(5-6):189-196.
18. Richard JM, Sancho H, Lepintre Y, Rodary J, Pierquin B. Intra-arterial methotrexate chemotherapy and telecobalt therapy in cancer of the oral cavity and oropharynx. *Cancer*. 1974;34(3):491-496.

19. Chhatui B, Devleena, Roy S, Maji T, Lahiri D, Biswas J. Immunomodulated anterior chemotherapy followed by concurrent chemoradiotherapy in locally advanced tongue cancer: An Institutional experience. *Indian Journal of Medical and Paediatric Oncology* 2015;36(1):43-48.
20. Depondt J, Gehanno P, Martin M, et al. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer. *Oncology*. 1993;50 Suppl 2:23-27.
21. Di Blasio B BW, Bozzetti A, Iotti C, Di Sarra S, Cocconi G. A prospective randomized trial in resectable head and neck carcinoma: loco-regional treatment with and without neoadjuvant chemotherapy. *Proc ASCO*. 1994 13:279
22. Head and Neck Contracts Group. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. *Cancer*. 1987;60(3):301-311.
23. Luboinski B. Preliminary results of a randomized study on preoperative intra-arterial chemotherapy combined with surgery and irradiation for carcinomas of the floor of the mouth. *Progress in clinical and biological research*. 1985;201:199-203.
24. Maipang T, Maipang M, Geater A, Panjapiyakul C, Watanaarepornchai S, Punperk S. Combination chemotherapy as induction therapy for advanced resectable head and neck cancer. *Journal of surgical oncology*. 1995;59(2):80-85.
25. Martin M, Lelièvre, Michel-Langlet P, et al. A randomized study of CDDP and 5-FU as neoadjuvant chemotherapy in head and neck cancer: an interim analysis. In: Banzet P, Holland JF, Khayat D, Weil M, eds. *Cancer treatment: an update* Paris Springer- Verlag 1994:214-218.
26. Paccagnella A, Orlando A, Marchiori C, et al. Phase III Trial of Initial Chemotherapy in Stage III or IV Head and Neck Cancers: a Study by the Gruppo di Studio sui Tumori della Testa e del Collo. *Journal of the National Cancer Institute*. 1994;86(4):265-272.
27. Richard JM, Kramar A, Molinari R, et al. Randomised EORTC head and neck cooperative group trial of preoperative intra-arterial chemotherapy in oral cavity and oropharynx carcinoma. *European journal of cancer (Oxford, England : 1990)*. 1991;27(7):821-827.
28. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. *The Laryngoscope*. 1988;98(11):1205-1211.
29. Volling P, Schroder M, Muller R, Ebeling O, Quirin R, Stennert E. Induction chemotherapy in primary resectable head and neck tumors - a prospective randomized trial. *International journal of oncology*. 1994;4(4):909-914.
30. Zhong LP, Zhang CP, Ren GX, et al. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. *Oncotarget*. 2015;6(21):18707-18714.
31. Holoye P, Grossman T, Toohill R, et al. Randomized study of adjuvant chemotherapy for head and neck cancer *Otolaryngol Head Neck Surg* 1985;93(6):712-717.
32. Toohill RJ, Anderson T, Byhardt RW, et al. Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report. *Archives of otolaryngology--head & neck surgery*. 1987;113(7):758-761.
33. Pearlman NW, Johnson FB, Braun TJ, et al. A prospective study of preoperative chemotherapy and split-course irradiation for locally advanced or recurrent oral/pharyngeal squamous carcinoma. *American Journal of Clinical Oncology*. 1985;8(6):490-496.
34. Brunin F, Rodriguez J, Jaulerry C, et al. [Role of neoadjuvant chemotherapy in the treatment of advanced head and neck tumors. Results of two randomized therapeutical trials conducted at the Institut Curie on 208 patients]. *Bulletin du cancer*. 1992;79(9):893-904.
35. Fazekas JT, Sommer C, Kramer S. Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cancers of the oral cavity, oropharynx, supraglottic larynx or hypopharynx. *International journal of radiation oncology, biology, physics*. 1980;6(5):533-541.
36. Jaulerry C, Rodriguez J, Brunin F, et al. Induction chemotherapy in advanced head and neck tumors: results of two randomized trials. *International journal of radiation oncology, biology, physics*. 1992;23(3):483-489.
37. Lewin F, Damber L, Jonsson H, et al. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized Phase III study. *Radiotherapy and Oncology*. 43(1):23-28.

38. Mazon JJ, Martin M, Brun B, et al. Induction chemotherapy in head and neck cancer: results of a phase III trial. *Head & neck*. 1992;14(2):85-91.
39. Salvajoli JV MH, Trippe N, Kowalski LP. A randomized trial of neoadjuvant vs concomitant chemotherapy vs radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma. *Eur Arch Otorhinolaryngol*. 1991;249(4):211-215.
40. Dalley D, Beller E, Aroney R, et al. The value of chemotherapy (CT) prior to definitive local therapy (DTL) in patients with locally advanced squamous cell carcinoma of the head and neck (HN) *Proc ASCO* 1995 14:247.
41. Bossi P, Lo Vullo S, Guzzo M, et al. Preoperative chemotherapy in advanced resectable OCSCC: Long-term results of a randomized phase III trial. *Annals of Oncology*. 2014;25(2):462-466.
Licitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. *J Clin Oncol*. 2003;21(2):327-33.
42. Hasegawa Y MH, Fukushima M, Kano M, Shimozato K. Potential suppression of distant and node metastasis by neoadjuvant chemotherapy in advanced head and neck cancer: result of a randomized trial. *Proc ASCO*. 1996;15:318.
43. Carugati A, Pradier R, A d. Combination chemotherapy pre-radical treatment for head and neck cancer: preliminary results of a randomized study. *Acta Oncol*. 1988; 249: 211-215
44. Zhong LP, Zhang CP, Ren GX, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2013;31(6):744-751.
45. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. *J Natl Cancer Inst*. 2008;100(4):261-269.
46. Patil K, Noronha, Joshi, Dhumal, Juvekar, Arya. NACT in locally advanced oral cancers : Does HPV make a difference? *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2015;33.
47. Kim R, Hahn S, Shin J, et al. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. *Cancer Research and Treatment : Official Journal of Korean Cancer Association* November 17, 2015 ed: Korean Cancer Association; 2015.doi: <http://dx.doi.org/10.4143/crt.2015.359>.

Figure 1: A flow chart of literature search methods




Figure 2: Quality assessment of studies gathered from the literature search

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Bossi et al 2014	+	+	+	+	+
Brunin et al 1989	?	?	+	+	+
Carugati et al 1988	?	?	?	?	?
Chhatui et al 2015	?	?	+	+	+
Dalley et al 1995	?	?	?	?	?
Depondi et al 1993	?	?	+	?	?
DiBlasio et al 1994	?	?	?	?	?
Fazekas et al 1980	+	+	?	+	+
Hasegawa et al 1996	?	?	?	?	?
Head and Neck Contracts 1990	+	+	+	+	+
Holoye et al 1983	?	?	+	+	+
Jaulery et al 1990	?	?	+	+	+
Lewin et al 1997	+	?	?	+	?
Lubinski et al 1985	?	?	+	?	+
Maipang et al 1995	?	?	+	+	+
Martin et al 1994	?	?	+	+	?
Mazeron et al 1992	+	?	+	+	+
Paccagnella et al 1994	+	+	+	+	+
Pearlman et al 1985	?	?	+	+	+
Richard et al 1974	+	+	+	+	+
Richard et al 1991	+	+	+	+	+
Sadighi et al 2015	?	?	-	-	?
Salvajoli et al 1991	?	?	?	?	?
Schuller et al 1988	+	?	+	+	+
Szpirglas et al 1988	?	?	+	?	?
Toohill et al 1987	?	?	+	+	?
Volling et al 1994	+	+	+	+	+
Zhong et al 2012, 2015	+	+	+	+	+

Figure 2: Overall Survival between induction chemotherapy and Locoregional treatment compared to locoregional treatment alone (a) standard meta-analysis (b) cumulative meta-analysis






Figure 4: Disease Free Survival among OSCC patients receiving induction chemotherapy and locoregional treatment versus locoregional treatment alone (a) standard meta-analysis (b) cumulative meta-analysis

(a)



(b)





Figure 4: Subset analysis of cisplatin - 5FU containing induction chemotherapy protocol in overall survival amongst patients receiving induction chemotherapy and locoregional treatment compared to locoregional treatment alone (a) standard meta-analysis (b) cumulative meta-analysis

(a)



(b)




Figure 8: Sensitivity analysis of locoregional recurrence amongst patients receiving ICT and locoregional treatment compared to locoregional treatment alone (a) standard meta-analysis (b) cumulative meta-analysis







Figure 7 : Distant metastasis amongst OSCC patients who recieved induction chemotherapy and locoregional treatment compared to locoregional treatment alone
 (a) standard meta-analysis (b) cumulative meta-analysis



Supplementary Data (online only)

[Click here to download Supplementary Data \(online only\): Supplemen table 1.docx](#)

Supplementary Data (online only)

[Click here to download Supplementary Data \(online only\): Suppl1-beggs funnel OS.tif](#)

Supplementary Data (online only)

[Click here to download Supplementary Data \(online only\): Supplfig 2- OS beggs and eggers.tif](#)

Supplementary Data (online only)

[Click here to download Supplementary Data \(online only\): Suppfigure 3 - LRO funnel plot.tif](#)

Supplementary Data (online only)

[Click here to download Supplementary Data \(online only\): Supplefig4- LRO begg and egggers test.tif](#)